Intrust Bank NA Makes New Investment in argenx SE (NASDAQ:ARGX)

Intrust Bank NA purchased a new position in argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 623 shares of the company's stock, valued at approximately $383,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Whipplewood Advisors LLC bought a new position in shares of argenx in the 4th quarter worth about $37,000. Global Retirement Partners LLC grew its holdings in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after purchasing an additional 48 shares during the period. Jones Financial Companies Lllp increased its stake in shares of argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of argenx by 78.6% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after purchasing an additional 33 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after purchasing an additional 21 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of ARGX traded down $34.95 on Friday, reaching $555.11. The company's stock had a trading volume of 547,357 shares, compared to its average volume of 296,784. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The stock has a market capitalization of $33.73 billion, a P/E ratio of -630.81 and a beta of 0.60. The stock's 50 day simple moving average is $621.43 and its two-hundred day simple moving average is $602.61.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. Analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on ARGX. Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research note on Tuesday, January 7th. Truist Financial reaffirmed a "buy" rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. JMP Securities increased their price objective on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research report on Tuesday, January 14th. Citigroup reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Finally, Oppenheimer increased their price target on shares of argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.